探索迪奥斯基宁作为对抗神经退行性疾病的Semaforin-4D抗剂的治疗潜力
Ayushi Gupta1, Princy Choudhary2, Sneha Ranjan1
1Department of Applied Sciences, Indian Institute of Information Technology, Allahabad, India.
Archives of biochemistry and biophysics
|February 27, 2025
概括
来自Piper物种的植物化学物质迪奥斯基宁,通过抑制Sema4D,在治疗神经退行性疾病方面表现有前途. 在实验室研究中,这种化合物增强了细胞活力,并保护了细胞免受氧化应激.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 神经退行性疾病对健康构成重大挑战,原因是人们对神经退行性疾病机制的了解不足,治疗效果有限.
- 目前神经退行性疾病的治疗方法往往缺乏必要的疗效,突出显示了对新型治疗点和药物的需求.
- Sema4D被确定为缓解神经炎症和脱髓化在阿尔茨海默病,帕金森病和多发性硬化症等疾病中的关键目标.
研究的目的:
- 评估Piper nigrum和Piper betle中的生物活性植物化学物质作为对Sema4D的对抗剂的有效性.
- 研究植物化学物质迪奥斯基宁作为神经退行性疾病治疗剂的潜力.
主要方法:
- 进行了包括分子对接和分子动力学模拟 (RMSF,RMSD,PCA,SASA,FEL) 在内的体研究,以评估Diosgenin与Sema4D的结合亲和力和稳定性.
- 进行了体外实验,以评估迪奥斯基宁对PC12细胞细胞活力,增殖和抗氧化应激诱导损伤的保护的影响.
主要成果:
- 迪奥斯基因与Sema4D在中显示出强大的结合亲和力 (-8.84 kcal/mol).
- 分子动力学模拟证实了Diosgenin-Sema4D复合物的稳定性超过100 ns.
- 在体外,迪奥斯基宁增强了PC12细胞的活力和增殖,并提供了对氧化应激的保护.
结论:
- 迪奥斯基宁显示出作为针对神经退行性疾病的Sema4D治疗剂的显著潜力.
- 进一步的体内研究是必要的,以评估在临床前和临床环境中的生物可用性,毒性和治疗疗效.
更多相关视频
09:17Assessing Neurodegenerative Phenotypes in Drosophila Dopaminergic Neurons by Climbing Assays and Whole Brain Immunostaining
Published on: April 24, 2013
19.2K
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
1.7K
相关概念视频
siRNA - Small Interfering RNAs
16.5K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.5K
Dipeptidyl Peptidase 4 Inhibitors
161
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
161
